Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)

CAS: blood clotting factor 11, 9013-55-2; thrombin, 9002-04-4; tissue plasminogen activator, 105913-11-9; protein C, 60202-16-6; Carboxypeptidase U, 3.4.17.20; Protein C; Tissue Plasminogen Activator, 3.4.21.68

Fibrinolytic efficacy of amediplase, tenecteplase and scu-PA in different external plasma clot lysis models

In this study, the in-vitro fibrinolytic efficacy of Tenecteplase, Amediplase and scu-PA was investigated in different external lysis models by measuring the lysis of human plasma clots after the addition of the plasminogen activators (PAs) to the surrounding plasma. The effect of TAFI was examined for each PA by neutralising TAFIa with potato...

Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2tu-PA)

Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...

Acceleration of fibrinolysis by high-frequency ultrasound: The contribution of acoustic streaming and temperature rise

High-frequency ultrasound has been shown to accelerate enzymatic fibrinolysis. One of the supposed mechanisms of this effect is the enhancement of mass transport by acoustic streaming, i.e., ultrasound-induced macroscopic flow around the clot. In this study, which is aimed at further elucidating the mechanisms of the acceleration of fibrinolysis...

Plasma clearance of urokinase-type plasminogen activator

Evaluation of a bioimmuno assay for t-PA activity and its relation to PAI-1 activity and antigen levels

A chromogenic bioimmunoassay method for determination of t-PA activities has been evaluated on plasmas from healthy individuals and from thromboembolic patients. The assay consists of an initial binding and washing step, whereby plasma t-PA is bound to a specific monoclonal t-PA antibody, which is coated on to microplate wells, followed by a...

Interaction of reteplase with heparin. A comparison between reteplase and alteplase

Reteplase is a protein consisting of the kringle-2 and protease domains of tissue-type plasminogen activator (t-PA). Because intravenous heparin will be used as an adjunct to thrombolytic therapy with reteplase, we investigated the interactions in vitro between heparin and reteplase as well as between heparin and recombinant t-PA (alteplase) as...

Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin

Staphylokinase (STA), a protein of bacterial origin, induces highly fibrin-specific thrombolysis both in human plasma in vitro and in pilot clinical trials. Using fluorescence microscopy, we investigated the spatial distribution of fluorescein isothiocyanate (FITC)-labeled STA during lysis of a plasma clot and its binding to purified fibrin...

Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis: Study with confocal microscopy

Binding of components of the fibrinolytic system to fibrin is important for the regulation of fibrinolysis. In this study, decomposition of the fibrin network and binding of plasminogen and plasminogen activators (PAs) to fibrin during lysis of a plasma clot were investigated with confocal microscopy using fluorescein-labeled preparations of...

Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age

Each of three distinct, concentric layers of human arterial thrombi, was analysed immunochemically for the plasminogen and fibrin content, and for the ex vivo susceptibility to thrombolysis by various thrombolytic agents in a saline or plasma milieu. The age of the thrombus layer determined: (a) the plasminogen content; (b) the fibrin content,...

Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products

Chemicals/CAS: Blood Coagulation Factors; Tissue Plasminogen Activator, EC 3.4.21.68

Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor- and kringle 1-domains

Chemicals/CAS: Recombinant Proteins; Tissue Plasminogen Activator, EC 3.4.21.68

Composition and susceptibility to thrombolysis of pathological human arterial thrombi

Chemicals/CAS: Plasminogen, 9001-91-6; Streptokinase, EC 3.4.-.

Impact of endothelial activation on fibrinolysis and local proteolysis in tissue repair

Chemicals/CAS: Cytokines; Plasminogen Activator Inhibitor 1; plasminogen activator, urokinase receptors; Plasminogen, 9001-91-6; Receptors, Cell Surface; Urinary Plasminogen Activator, EC 3.4.21.73.

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: Why they are used and how they are made

The generation of the proteolytic enzyme plasmin from its inactive precursor plasminogen, mediated by so called plasminogen activators, is the essential step in thrombolytic therapy. Plasmin is responsible for the degradation of the insoluble fibrin, the major component of a thrombus, to soluble fibrin degradation products. So far, the use of...